Related Research Articles
Charles Franklin Kettering sometimes known as Charles Fredrick Kettering was an American inventor, engineer, businessman, and the holder of 186 patents. He was a founder of Delco, and was head of research at General Motors from 1920 to 1947. Among his most widely used automotive developments were the electrical starting motor and leaded gasoline. In association with the DuPont Chemical Company, he was also responsible for the invention of Freon refrigerant for refrigeration and air conditioning systems. At DuPont he also was responsible for the development of Duco lacquers and enamels, the first practical colored paints for mass-produced automobiles. While working with the Dayton-Wright Company he developed the "Bug" aerial torpedo, considered the world's first aerial missile. He led the advancement of practical, lightweight two-stroke diesel engines, revolutionizing the locomotive and heavy equipment industries. In 1927, he founded the Kettering Foundation, a non-partisan research foundation, and was featured on the cover of Time magazine in January 1933.
Mansukh C. Wani,, was a principal scientist (emeritus) at the Research Triangle Institute in North Carolina. He was co-discoverer of Taxol and camptothecin, two anti-cancer drugs considered standard in the treatment to fight ovarian, breast, lung and colon cancers. In 2000, Wani received an award for applied research in medicine, the Charles F. Kettering Prize, from the General Motors Cancer Research Foundation.
Lasker–DeBakey Clinical Medical Research Award is one of four annual awards presented by the Lasker Foundation. The Lasker–DeBakey award is given to honor outstanding work for the understanding, diagnosis, prevention, treatment, and cure of disease. This award was renamed in 2008 in honor of Michael E. DeBakey. It was previously known as the Albert Lasker Award for Clinical Medical Research.
The Canada Gairdner International Award is given annually by the Gairdner Foundation at a special dinner to five individuals for outstanding discoveries or contributions to medical science. Receipt of the Gairdner is traditionally considered a precursor to winning the Nobel Prize in Medicine; as of 2020, 98 Nobel Prizes have been awarded to prior Gairdner recipients.
Moses Judah Folkman was an American biologist and pediatric surgeon best known for his research on tumor angiogenesis, the process by which a tumor attracts blood vessels to nourish itself and sustain its existence. He founded the field of angiogenesis research, which has led to the discovery of a number of therapies based on inhibiting or stimulating neovascularization.
Delco Electronics Corporation was the automotive electronics design and manufacturing subsidiary of General Motors based in Kokomo, Indiana, that manufactured Delco Automobile radios and other electric products found in GM cars. In 1972, General Motors merged it with the AC Electronics division and it continued to operate as part of the Delco Electronics division of General Motors. When the corporation acquired the Hughes Aircraft Company, Delco was merged with it to form Hughes Electronics as an independent subsidiary.
Emil "Tom" Frei III was an American physician and oncologist. He was the former director and former physician-in-chief of the Dana–Farber Cancer Institute in Boston, Massachusetts. He was also the Richard and Susan Smith Distinguished Professor of Medicine at Harvard Medical School.
Virgil Craig Jordan,, was an American and British scientist specializing in drugs for breast cancer treatment and prevention. He was Professor of Breast Medical Oncology, and Professor of Molecular and Cellular Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas. Previously, he was Scientific Director and Vice Chairman of Oncology at the Lombardi Comprehensive Cancer Center of Georgetown University. Jordan was the first to discover the breast cancer prevention properties of tamoxifen and the scientific principles for adjuvant therapy with antihormones. His later work branched out into the prevention of multiple diseases in women with the discovery of the drug group, selective estrogen receptor modulator (SERMs). He later worked on developing a new Hormone Replacement Therapy (HRT) for post-menopausal women that prevents breast cancer and does not increase the risk of breast cancer.
The Passano Foundation, established in 1945, provides an annual award to a research scientist whose work – done in the United States – is thought to have immediate practical benefits. Many Passano laureates have subsequently won the Nobel Prize.
The William B. Coley Award for Distinguished Research in Basic and Tumor Immunology is presented annually by the Cancer Research Institute, to scientists who have made outstanding achievements in the fields of basic and tumor immunology and whose work has deepened our understanding of the immune system's response to disease, including cancer.
David Haussler is an American bioinformatician known for his work leading the team that assembled the first human genome sequence in the race to complete the Human Genome Project and subsequently for comparative genome analysis that deepens understanding the molecular function and evolution of the genome.
The Charles S. Mott Prize was awarded annually by the General Motors Cancer Research Foundation as one of a trio of scientific prizes entirely devoted to cancer research, the other two being the Charles F. Kettering Prize and the Alfred P. Sloan, Jr. Prize. The prizes, worth US$250,000, were awarded annually between 1979 and 2005. The awards were generally considered the most prestigious in the field.
Emil J. Freireich was an American hematologist, oncologist, and cancer biologist. He was recognized as a pioneer in the treatment of cancer and use of chemotherapy and is often known as the father of modern leukemia therapy.
Napoleone Ferrara is an Italian-American molecular biologist who joined University of California, San Diego Moores Cancer Center in 2013 after a career in Northern California at the biotechnology giant Genentech, where he pioneered the development of new treatments for angiogenic diseases such as cancer, age-related macular degeneration (AMD), and diabetic retinopathy. At Genentech, he discovered VEGF—and made the first anti-VEGF antibody—which suppresses growth of a variety of tumors. These findings helped lead to development of the first clinically available angiogenesis inhibitor, bevacizumab (Avastin), which prevents the growth of new blood vessels into a solid tumor and which has become part of standard treatment for a variety of cancers. Ferrara's work led also to the development of ranibizumab (Lucentis), a drug that is highly effective at preventing vision loss in intraocular neovascular disorders.
Nicholas B. Lydon FRS is a British scientist and entrepreneur. In 2009, he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, also known as Imatinib, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukaemia (CML), which converted a fatal cancer into a manageable chronic condition.
Joan Massagué, is a Spanish biologist and the current director of the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center. He is also an internationally recognized leader in the study of both cancer metastasis and growth factors that regulate cell behavior, as well as a professor at the Weill Cornell Graduate School of Medical Sciences.
Thomas J. Kelly is an American cancer researcher whose work focuses on the molecular mechanisms of DNA replication. Kelly is director of the Sloan-Kettering Institute, the basic research arm of the Memorial Sloan-Kettering Cancer Center. He holds the Center's Benno C. Schmidt Chair of Cancer Research.
The Alfred P. Sloan Jr. Prize was a $250,000 award given by the General Motors Cancer Research Foundation for outstanding oncological research.
The Paul Marks Prize for Cancer Research is awarded by the Memorial Sloan Kettering Cancer Center to recognize cancer researchers who are making significant contributions to the understanding of cancer or are improving the treatment of the disease through basic or clinical research.
Angela Hartley Brodie was a British biochemist who pioneered development of steroidal aromatase inhibitors in cancer research. Born in Lancashire, Brodie studied chemical pathology to a doctoral level in Sheffield and was awarded a fellowship sponsored by National Institutes of Health. After 17 years of working in Shrewsbury, Massachusetts on oral contraceptives with Harry Brodie, whom she married, she switched focus to the effects of the oestrogen-producing enzyme, aromatase, on breast cancer.
References
- ↑ "Laureates: General Motors Cancer Research Awards". Cancer Research. 59 (7 Supplement): 1673s. 1 March 1999. ISSN 0008-5472 . Retrieved 20 August 2018.
- ↑ "GM Cancer Previous Prize Winners". General Motors. Archived from the original on 13 March 2007. Retrieved 12 August 2012.
- ↑ "Napoleone Ferrara wins 2006 GM Cancer Research Award". Cancer Biology & Therapy. 5 (7): 708–709. July 2006. doi: 10.4161/cbt.5.7.3155 . PMID 17022136.